LFC131 peptide-conjugated polymeric nanoparticles for the effective delivery of docetaxel in CXCR4 overexpressed lung cancer cells

Colloids and Surfaces B: Biointerfaces

Volumn 133, Issue , 2015, Pages 43-50

  Wang, Ruo Tian ^a   Zhi, Xiu Yi ^a   Yao, Shu Yang ^a   Zhang, Yi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

CXCR4; Docetaxel; LFC131 peptide; Lung cancers; Polymeric nanoparticles; Targeted approach

Indexed keywords

BINS; BIOLOGICAL ORGANS; CELL DEATH; CYTOLOGY; CYTOTOXICITY; DISEASES; ELECTRIC FREQUENCY CONTROL; FLUORESCENCE; MOBILE SECURITY; MULTILAYERS; NANOPARTICLES; PEPTIDES;

CXCR4; DOCETAXEL; LUNG CANCER; POLYMERIC NANOPARTICLES; TARGETED APPROACH;

CELLS;

CASPASE 3; CHEMOKINE RECEPTOR CXCR4; DOCETAXEL; LFC131 PEPTIDE; NANOCARRIER; NANOPARTICLE; O CARBOXYMETHYL CHITOSAN NANOPARTICLE; PEPTIDE DERIVATIVE; POLYMER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE; TAXOID;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TUMOR LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LUNG CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; CHEMISTRY; DRUG SCREENING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NANOPARTICLES; OLIGOPEPTIDES; POLYMERS; TAXOIDS;

EID: 84931263844     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.05.030     Document Type: Article

References (21)

1. Jemal A., Thun M.J., Ries L.A., Howe H.L., Weir H.K., Center M.M., Ward E., Wu X.C., Eheman C., Anderson R., Ajani U.A., Kohler B., Edwards B.K. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J. Natl. Cancer Inst. 2008, 100:1672-1694.
2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA Cancer J. Clin. 2014, 64:9-29.
3. Yang Y., Hu Y.X., Wang Y.H., Li J., Liu F., Huang L. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol. Pharm. 2012, 9:2280-2289.
4. Lv P.P., Wei W., Yue H., Yang T.Y., Wang L.Y., Ma G.H. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration. Biomacromolecules 2011, 12:4230-4239.
5. Haijun Y., Yonglong Z., Lei J., Qi Y., Xinyu H., Lingli C., Zhiwen Z., Wangwen G., Yaping L. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials 2013, 24:2738-2747.
6. Rosell R., Bivona T.G., Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013, 382:720-731.
7. Montero A., Fossella F., Hortobagyi G., Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005, 6:229-239.
8. Saloustros E., Georgoulias V. Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 2008, 8:1207-1222.
9. Karve S., Werner M.E., Sukumar R., et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8230-8235.
10. Hwang H.Y., Kim I.S., Kwon I.C., Kim Y.H. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycolchitosan nanoparticles. J. Control. Release 2008, 128:23-31.
11. Dewan M.Z., Ahmed S., Iwasaki Y., Ohba K., Toi M., Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed. Pharmacother. 2006, 60:273-276.
12. Tang C.H., Tan T.W., Fu W.M., Yang R.S. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 2008, 29:35-43.
13. Phillips R.J., Burdick M.D., Lutz M., Belperio J.A., Keane M.P., Strieter R.M. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med. 2003, 167:1676-1686.
14. Arya M., Ahmed H., Silhi N., Williamson M., Patel H.R. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand receptor) interaction in cancer cell migration. Tumour Biol. 2007, 28:123-131.
15. Tsutsumi H., Tanaka T., Ohashi N., Masuno H., Tamamura H., Hiramatsu K., Araki T., Ueda S., Oishi S., Fujii N. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers 2007, 88:279-289.
16. Tamamura H., Xu Y., Hattori T., Zhang X., Arakaki R., Kanbara K., Omagari A., Otaka A., Ibuka T., Yamamoto N., Nakashima H., Fujii N. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. 1998, 253:877-882.
17. Anitha A., Chennazhi K.P., Nair S.V., Jayakumar R. 5-Flourouracil loaded N,O-carboxymethyl chitosan nanoparticles as an anticancer nanomedicine for breast cancer. J. Biomed. Nanotechnol. 2012, 8:1-14.
18. Lee H., Fonge H., Hoang B., Reilly R.M., Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol. Pharm. 2010, 7:1195-1208.
19. Phillips R.J., Mestas J., Gharaee-Kermani M., Burdick M.D., Sica A., Belperio J.A., Keane M.P., Strieter R.M. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J. Biol. Chem. 2005, 253:22473-22481.
20. Fahham D., Weiss I.D.M., et al. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 2012, 144:1167-1175.
21. Pei-Chin L., Chien-Hui L. Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells. Life Sci. 2005, 76:1623-1639.